




RealRate

PHARMACEUTICAL 2017

Lixte Biotechnology Holdings INC
Rank 302 of 308



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Lixte Biotechnology Holdings INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lixte Biotechnology Holdings INC compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 5.6% points. The greatest weakness of Lixte Biotechnology Holdings INC is the variable Assets, reducing the Economic Capital Ratio by 124% points.

The company's Economic Capital Ratio, given in the ranking table, is 17%, being 227% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	433
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	219
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	0.18
Other Revenues	0
Property and Equipment	0
Research and Development	1,301
Selling, General and Administrative Expense	834

Output Variable	Value in 1000 USD
Assets	433
Liabilities	219
Expenses	2,135
Revenues	0
Stockholders Equity	215
Net Income	-2,135
Comprehensive Net Income	-2,135
BaseVar	1,394
ECR before LimitedLiability	-511%
Economic Capital Ratio	17%